{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-039518","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2026-06-01T20:22:15+00:00","discovered_at":"2026-06-01T20:23:00.247923+00:00","generated_at":"2026-06-01T20:35:07.666843+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Esperion shareholders approve 7M-share increase to 2022 equity incentive plan","bullets":["Stockholders approved Plan Amendment increasing 2022 Plan authorized shares by 7,000,000.","J. Martin Carroll and Sheldon L. Koenig elected as Class I directors for terms ending 2029.","Advisory vote on executive compensation approved with ~95.7M for, ~34.9M against.","Ratification of Ernst & Young as auditor for FY2026 passed with ~167.1M for.","All proposals passed at May 28, 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039518","json":"https://secwatch.observer/filing/0001628280-26-039518.json","markdown":"https://secwatch.observer/filing/0001628280-26-039518.md","text":"https://secwatch.observer/filing/0001628280-26-039518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T20:35:07.666843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0910c3811492c95f2d31303f1f3817387db9fd7a","claim":"Esperion Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-05-28 meeting.","evidence_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","confidence":0.9},{"claim_id":"2536072c08ba76ad3f635334fd9ca34398baa79a","claim":"Esperion Therapeutics, Inc. shareholders approved Amendment to 2022 Equity Incentive Plan to increase shares by 7,000,000 at the 2026-05-28 meeting.","evidence_excerpt":"The Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 108,150,213 22,489,001 454,840 46,114,802","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","confidence":0.9},{"claim_id":"37f9ebbee0d9198d1ed11c68483cb682f191bd93","claim":"Esperion Therapeutics, Inc. shareholders approved Election of two Class I directors: J. Martin Carroll and Sheldon L. Koenig at the 2026-05-28 meeting.","evidence_excerpt":"The Company’s stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class I directors as follows: Class I Director Nominee For Withhold Broker Non-Votes J. Martin Carroll 105,082,565 26,011,489 46,114,802 Sheldon L. Koenig 109,672,941 21,421,113 46,114,802","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","confidence":0.9},{"claim_id":"c699dd06e484bbd03024093ebf299b6d17c92d2f","claim":"Esperion Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-05-28 meeting.","evidence_excerpt":"The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 95,650,226 34,866,033 577,795 46,114,802","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001108524-26-000131","ticker":"CRM","company_name":"Salesforce, Inc.","filed_at":"2026-06-01T20:43:09+00:00","headline":"Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected","event_type":"other_material","sec_items":["5.07","5.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108524-26-000131","json":"https://secwatch.observer/filing/0001108524-26-000131.json","markdown":"https://secwatch.observer/filing/0001108524-26-000131.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/0001108524-26-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/crm-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"Advisory vote to approve the fiscal 2026 compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 493,864,228 117,716,717 668,510 102,463,325","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/0001108524-26-000131-index.htm"}},{"accession":"0000790816-26-000019","ticker":null,"company_name":"BRANDYWINE OPERATING PARTNERSHIP, L.P.","filed_at":"2026-06-01T20:30:42+00:00","headline":"Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP","event_type":"other_material","sec_items":["1.01","2.03","5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000790816-26-000019","json":"https://secwatch.observer/filing/0000790816-26-000019.json","markdown":"https://secwatch.observer/filing/0000790816-26-000019.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/790816/000079081626000019/bdn-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"PROPOSAL 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for calendar year 2026. Votes For Votes Against Abstentions 134,853,955 7,100,190 646,621","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm"}},{"accession":"0000908937-26-000015","ticker":"SIRI","company_name":"SIRIUS XM HOLDINGS INC.","filed_at":"2026-06-01T20:28:55+00:00","headline":"Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000908937-26-000015","json":"https://secwatch.observer/filing/0000908937-26-000015.json","markdown":"https://secwatch.observer/filing/0000908937-26-000015.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/0000908937-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/siri-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"Election of Directors The holders of our common stock elected the persons listed below as Class I directors. Votes Cast For Votes Withheld Broker Non-Votes Eddy W. Hartenstein 229,472,971 4,921,855 51,448,019 Kristina M. Salen 231,643,217 2,751,609 51,448,019 Jennifer C. Witz 230,660,585 3,734,241 51,448,019 The holders of our common stock elected the persons listed below as Class II directors. Votes Cast For Votes Withheld Broker Non-Votes Evan D. Malone 230,881,893 3,512,933 51,448,019 Jonelle Procope 210,894,725 23,500,101 51,448,019 Anjali Sud 213,150,753 21,244,073 51,448,019","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/0000908937-26-000015-index.htm"}},{"accession":"0000092380-24-000094","ticker":"LUV","company_name":"SOUTHWEST AIRLINES CO","filed_at":"2024-05-20T23:59:59+00:00","headline":"Southwest shareholders approve amended equity plan with 4.75M share increase; all directors elected","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000092380-24-000094","json":"https://secwatch.observer/filing/0000092380-24-000094.json","markdown":"https://secwatch.observer/filing/0000092380-24-000094.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/92380/000009238024000094/0000092380-24-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/92380/000009238024000094/luv-20240515.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"3. Proposal 3 – Approval of the Southwest Airlines Co. Amended and Restated 2007 Equity Incentive Plan: VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 408,346,613 28,870,401 1,635,532 90,613,942","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/92380/000009238024000094/0000092380-24-000094-index.htm"}},{"accession":"0001193125-24-141703","ticker":null,"company_name":"Regulus Therapeutics Inc.","filed_at":"2024-05-17T23:59:59+00:00","headline":"Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-141703","json":"https://secwatch.observer/filing/0001193125-24-141703.json","markdown":"https://secwatch.observer/filing/0001193125-24-141703.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/d829869d8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm"}},{"accession":"0001628280-24-024025","ticker":"OSUR","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2024-05-17T23:59:59+00:00","headline":"OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability","event_type":"other_material","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-024025","json":"https://secwatch.observer/filing/0001628280-24-024025.json","markdown":"https://secwatch.observer/filing/0001628280-24-024025.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000162828024024025/0001628280-24-024025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000162828024024025/osur-20240514.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"ITEM 1 . Election of two Class III Directors for Terms Ending in 2027. NAME Votes For Votes Against Abstentions Broker Non-Votes Nancy J. Gagliano, M.D. 57,243,711 4,832,639 46,575 5,007,157 Lelio Marmora 57,332,773 4,732,865 57,287 5,007,157","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1116463/000162828024024025/0001628280-24-024025-index.htm"}},{"accession":"0001079973-24-000772","ticker":null,"company_name":"Nemaura Medical Inc.","filed_at":"2024-05-17T23:59:59+00:00","headline":"Shareholders approve reverse stock split authorization at ratio of 1:10 to 1:150","event_type":"other_material","sec_items":["5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-24-000772","json":"https://secwatch.observer/filing/0001079973-24-000772.json","markdown":"https://secwatch.observer/filing/0001079973-24-000772.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1602078/000107997324000772/0001079973-24-000772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1602078/000107997324000772/nmra_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"On May 9, 2024, the Shareholders of Nemaura Medical Inc. (the “Company”) approved by written consent to authorize amendments to the Articles of Incorporation of the Company (the “Articles”) to effect a reverse stock split of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) ranging in ratio between 1-for-10 and 1-for-150, with one share of Common Stock being issued for a range of between each 10 and 150 shares of Common Stock issued and outstanding, with such final ratio to be determined by the Board following approval thereof by the shareholders of the Company, with any fractional shares of Common Stock resulting therefrom being rounded up to the nearest whole share of Common Stock (the “Reverse Split”), and to amend the Articles to effect the Reverse Split.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1602078/000107997324000772/0001079973-24-000772-index.htm"}},{"accession":"0001193125-24-141718","ticker":null,"company_name":"INTEVAC INC","filed_at":"2024-05-17T23:59:59+00:00","headline":"Stockholders approve share increases for ESPP and equity incentive plan at 2024 annual meeting","event_type":"other_material","sec_items":["5.02","5.07"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-141718","json":"https://secwatch.observer/filing/0001193125-24-141718.json","markdown":"https://secwatch.observer/filing/0001193125-24-141718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001902/000119312524141718/0001193125-24-141718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001902/000119312524141718/d819626d8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","comparable_excerpt":"Proposal 5: Advisory Approval of Named Executive Officer Compensation Intevac’s stockholders approved, on a non-binding, advisory basis, the compensation of Intevac’s named executive officers.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1001902/000119312524141718/0001193125-24-141718-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}